Thomson Reuters Cortellis Competitive Intelligence
Read the companion parts of this report on Brazil , Russia, and India.
4E: Late-stage trials are the most prevalent in India, with top therapeutic areas mimicking the global trend: diabetes, pulmonary diseases, and rheumatoid arthritis.
5A: China is the only BRIC country seeing an increase in the amount of clinical trials they are initiating every year. And clearly, large pharma lags behind Chinese-based trial initiations in that country. Recent developments in partnerships include AstraZeneca’s with Beijing’s premier clinical research laboratory, Pharmaron. Extensive networks of on-ground expertise with CROs is growing with entities like Novartis, Quintiles, Parexel, Covance’s central laboratory, and Catalant’s recently opened clinical trial supply facility in shanghai.
5E: Phase I trials must be performed in China with Chinese patients for all new drugs not already registered in another country. Due to the high incidence of local sponsors, however, early-stage trials are relatively elevated compared to other BRIC countries. Phase III trials are being initiated in oncology and pulmonology in numbers close to those of early-stage trials, which focus mainly on oncology.
SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.